Europe Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$184.6

Forecast, 2030 (US$M)

$256.1

CAGR, 2024 - 2030

4.8%

Report Coverage

Europe

Europe idiopathic thrombocytopenic purpura therapeutics market, 2018-2030 (US$M)

Related Markets

Global Idiopathic Thrombocytopenic Purpura Therapeutics Industry Outlook

North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook

Asia Pacific Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook

Latin America Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook

MEA Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook

Europe idiopathic thrombocytopenic purpura therapeutics market highlights

The Europe idiopathic thrombocytopenic purpura therapeutics market generated a revenue of USD 184.6 million in 2023.
The market is expected to grow at a CAGR of 4.8% from 2024 to 2030.
In terms of segment, acute itp was the largest revenue generating disease type in 2023.
Acute ITP is the most lucrative disease type segment registering the fastest growth during the forecast period.

Europe data book summary

Market revenue in 2023	USD 184.6 million
Market revenue in 2030	USD 256.1 million
Growth rate	4.8% (CAGR from 2023 to 2030)
Largest segment	Acute itp
Fastest growing segment	Acute ITP
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Acute ITP
Key market players worldwide	Amgen Inc, Roche, Grifols SA Ordinary Shares - Class A, GSK PLC, Intromedic, Medtronic PLC, FUJIFILM Holdings Corp, Olympus Corp

Other key industry trends

In terms of revenue, Europe region accounted for 28.4% of the global idiopathic thrombocytopenic purpura therapeutics market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 193.1 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Idiopathic Thrombocytopenic Purpura Therapeutics Market Scope

Idiopathic thrombocytopenic purpura therapeutics market segmentation & scope

Disease Type

Acute ITP

Chronic

Others

Product

Corticosteroids

IVIG

Anti-D Immunoglobulins

TPO-RA

Others

Regions

Latin America

Europe

North America

Middle East & Africa

Asia Pacific

Countries

Argentina

Brazil

Mexico

Denmark

Germany

France

Spain

Sweden

Norway

Italy

U.S.

Canada

UAE

Saudi Arabia

South Africa

Kuwait

Thailand

South Korea

Japan

India

China

Australia

Idiopathic Thrombocytopenic Purpura Therapeutics Market Companies

Name	Profile	# Employees	HQ	Website

Europe idiopathic thrombocytopenic purpura therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to idiopathic thrombocytopenic purpura therapeutics market will help companies and investors design strategic landscapes.

Acute itp was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Europe idiopathic thrombocytopenic purpura therapeutics market based on acute itp covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Europe idiopathic thrombocytopenic purpura therapeutics market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Europe idiopathic thrombocytopenic purpura therapeutics market databook

Our clientele includes a mix of idiopathic thrombocytopenic purpura therapeutics market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Europe idiopathic thrombocytopenic purpura therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe idiopathic thrombocytopenic purpura therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list